Showing results (1-10 of 82) with videos related to
Sort By:
Pageof 9
Expert Opinion on Investigational Drugs|May 20, 2011
Amonafide: a potential role in treating acute myeloid leukemiaSteven L Allen, Ante S LundbergLeukemia Research|September 15, 2009
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemiaSteven L Allen, Jonathan E Kolitz, Ante S Lundberg, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 5, 2006
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa)Kelly A Tammaro, Patricia D Baldwin, Ante S LundbergBiopharmaceutics & Drug Disposition|October 29, 2009
Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphateWei Yin, Elena V Karyagina, Ante S Lundberg, et al.Blood|August 24, 2011
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseasesMasha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 19, 2014
Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant EnterococcusKhilna Patel, Rubiya Kabir, Samrah Ahmad, et al.Anti-Cancer Drugs|July 3, 2008
In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemiaAnthony Calabro, Julia Tai, Steven L Allen, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 2, 2013
Clofarabine-induced kidney toxicityKenar D Jhaveri, Shailaja Chidella, Steven L Allen, et al.Arthritis and Rheumatism|February 23, 2012
Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumabIuliana Shapira, Danieli Andrade, Steven L Allen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.Pageof 9